BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guisado-Vasco P, Valderas-Ortega S, Carralón-González MM, Roda-Santacruz A, González-Cortijo L, Sotres-Fernández G, Martí-Ballesteros EM, Luque-Pinilla JM, Almagro-Casado E, La Coma-Lanuza FJ, Barrena-Puertas R, Malo-Benages EJ, Monforte-Gómez MJ, Diez-Munar R, Merino-Lanza E, Comeche-Casanova L, Remirez-de-Esparza-Otero M, Correyero-Plaza M, Recio-Rodríguez M, Rodríguez-López M, Sánchez-Manzano MD, Andreu-Vázquez C, Thuissard-Vasallo IJ, María-Tomé JME, Carnevali-Ruiz D. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). EClinicalMedicine 2020;28:100591. [PMID: 33078138 DOI: 10.1016/j.eclinm.2020.100591] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Yadav DK, Adhikari VP, Ling Q, Liang T. Immunosuppressants in Liver Transplant Recipients With Coronavirus Disease 2019: Capability or Catastrophe?-A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:756922. [PMID: 34859012 DOI: 10.3389/fmed.2021.756922] [Reference Citation Analysis]
2 Wen S, Prasad A, Freeland K, Podury S, Patel J, Subedi R, Khan E, Tandon M, Kataria S, Kimble W, Sriwastava S. Clinical Characteristics and Outcomes of COVID-19 in West Virginia. Viruses 2021;13:835. [PMID: 34063160 DOI: 10.3390/v13050835] [Reference Citation Analysis]
3 Sauerhering L, Kuznetsova I, Kupke A, Meier L, Halwe S, Rohde C, Schmidt J, Morty RE, Danov O, Braun A, Vadász I, Becker S, Herold S. Cyclosporin A Reveals Potent Antiviral Effects in Preclinical Models of SARS-CoV-2 Infection. Am J Respir Crit Care Med 2022. [PMID: 35167409 DOI: 10.1164/rccm.202108-1830LE] [Reference Citation Analysis]
4 Dittmar M, Lee JS, Whig K, Segrist E, Li M, Kamalia B, Castellana L, Ayyanathan K, Cardenas-Diaz FL, Morrisey EE, Truitt R, Yang W, Jurado K, Samby K, Ramage H, Schultz DC, Cherry S. Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. Cell Rep 2021;35:108959. [PMID: 33811811 DOI: 10.1016/j.celrep.2021.108959] [Cited by in Crossref: 27] [Cited by in F6Publishing: 38] [Article Influence: 27.0] [Reference Citation Analysis]
5 Saied EM, El-Maradny YA, Osman AA, Darwish AMG, Abo Nahas HH, Niedbała G, Piekutowska M, Abdel-Rahman MA, Balbool BA, Abdel-Azeem AM. A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19. Pharmaceutics 2021;13:1759. [PMID: 34834174 DOI: 10.3390/pharmaceutics13111759] [Reference Citation Analysis]
6 Spini A, Giudice V, Brancaleone V, Morgese MG, De Francia S, Filippelli A, Ruggieri A, Ziche M, Ortona E, Cignarella A, Trabace L. Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. Pharmacol Res 2021;173:105848. [PMID: 34454035 DOI: 10.1016/j.phrs.2021.105848] [Reference Citation Analysis]
7 Chan KW, Yu KY, Lee PW, Lai KN, Tang SC. Global REnal Involvement of CORonavirus Disease 2019 (RECORD): A Systematic Review and Meta-Analysis of Incidence, Risk Factors, and Clinical Outcomes. Front Med (Lausanne) 2021;8:678200. [PMID: 34113640 DOI: 10.3389/fmed.2021.678200] [Reference Citation Analysis]
8 Mahamat-Saleh Y, Fiolet T, Rebeaud ME, Mulot M, Guihur A, El Fatouhi D, Laouali N, Peiffer-Smadja N, Aune D, Severi G. Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies. BMJ Open 2021;11:e052777. [PMID: 34697120 DOI: 10.1136/bmjopen-2021-052777] [Reference Citation Analysis]
9 Scharringa S, Hoffman T, van Kessel DA, Rijkers GT. Vaccination and their importance for lung transplant recipients in a COVID-19 world. Expert Rev Clin Pharmacol 2021;:1-13. [PMID: 34328054 DOI: 10.1080/17512433.2021.1961577] [Reference Citation Analysis]
10 Li X, Peng T. Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery. Front Pharmacol 2021;12:660710. [PMID: 34017257 DOI: 10.3389/fphar.2021.660710] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Prasad K, Ahamad S, Kanipakam H, Gupta D, Kumar V. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine. ACS Chem Neurosci 2021;12:930-44. [PMID: 33606519 DOI: 10.1021/acschemneuro.1c00019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Wan X, Wu X, Wang D, Tan X, Liu X, Fu Z, Jiang H, Zheng M, Li X. An inductive graph neural network model for compound-protein interaction prediction based on a homogeneous graph. Brief Bioinform 2022:bbac073. [PMID: 35275993 DOI: 10.1093/bib/bbac073] [Reference Citation Analysis]
13 May MR, Rübben A, Lennertz A, Vanstreels L, Leijs M. Dealing with Corticosteroid and High-Dose Cyclosporine Therapy in a Pyoderma Gangrenosum Patient Contracting a COVID-19 Infection. JPM 2022;12:173. [DOI: 10.3390/jpm12020173] [Reference Citation Analysis]
14 Khan FA, Stewart I, Fabbri L, Moss S, Robinson K, Smyth AR, Jenkins G. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax 2021;76:907-19. [PMID: 33579777 DOI: 10.1136/thoraxjnl-2020-215266] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
15 Ao G, Wang Y, Qi X, Nasr B, Bao M, Gao M, Sun Y, Xie D. The association between severe or death COVID-19 and solid organ transplantation: A systematic review and meta-analysis. Transplant Rev (Orlando) 2021;35:100628. [PMID: 34087553 DOI: 10.1016/j.trre.2021.100628] [Reference Citation Analysis]
16 Accinelli RA, Ynga-Meléndez GJ, León-Abarca JA, López LM, Madrid-Cisneros JC, Mendoza-Saldaña JD. Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate. Travel Med Infect Dis 2021;44:102163. [PMID: 34534686 DOI: 10.1016/j.tmaid.2021.102163] [Reference Citation Analysis]
17 Guemes-Villahoz N, Burgos-Blasco B, Perez-Garcia P, Fernández-Vigo JI, Morales-Fernandez L, Donate-Lopez J, Ramos-Amador JT, Garcia-Feijoo J. Retinal and peripapillary vessel density increase in recovered COVID-19 children by optical coherence tomography angiography. J AAPOS 2021:S1091-8531(21)00552-8. [PMID: 34687877 DOI: 10.1016/j.jaapos.2021.06.004] [Reference Citation Analysis]
18 Wang X, Wang Y, Lu H, Yan L. Traditional Chinese medicine for the prevention and treatment of COVID-19: A protocol for systematic review and network meta-analysis. Medicine (Baltimore) 2021;100:e28375. [PMID: 34967369 DOI: 10.1097/MD.0000000000028375] [Reference Citation Analysis]
19 Li Y, Deng Y, Ye L, Sun H, Du S, Huang H, Zeng F, Chen X, Deng G. Clinical Significance of Plasma D-Dimer in COVID-19 Mortality. Front Med (Lausanne) 2021;8:638097. [PMID: 34113629 DOI: 10.3389/fmed.2021.638097] [Reference Citation Analysis]
20 Sánchez-Pernaute O. Cyclosporine A and COVID19 - The COQUIMA cohort. EClinicalMedicine 2021;31:100679. [PMID: 33385128 DOI: 10.1016/j.eclinm.2020.100679] [Reference Citation Analysis]
21 AlBahrani S, Al-Tawfiq JA, Alshaer AR, Shilash A, Alswefy K, Al-Zayer RS, Abouelela AM. A Case Series of Severe Hospitalized COVID-19 Patients Treated with Tocilizumab and Glucocorticoids: A Report from Saudi Arabian Hospital. J Epidemiol Glob Health 2021;11:233-7. [PMID: 33605118 DOI: 10.2991/jegh.k.210112.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Ommati MM, Mobasheri A, Heidari R. Drug-induced organ injury in coronavirus disease 2019 pharmacotherapy: Mechanisms and challenges in differential diagnosis and potential protective strategies. J Biochem Mol Toxicol 2021;35:e22795. [PMID: 33973313 DOI: 10.1002/jbt.22795] [Reference Citation Analysis]
23 Schuurmans MM, Hage R. Cyclosporine A and COVID-19 - The COQUIMA cohort. EClinicalMedicine 2021;31:100680. [PMID: 33385129 DOI: 10.1016/j.eclinm.2020.100680] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Chen CX, Hu F, Wei J, Yuan LT, Wen TM, Gale RP, Liang Y. Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19). Leukemia 2021;35:1661-70. [PMID: 34002026 DOI: 10.1038/s41375-021-01264-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Schaffrath J, Brummer C, Wolff D, Holtick U, Kröger N, Bornhäuser M, Kraus S, Hilgendorf I, Blau I, Penack O, Wittke C, Steiner N, Nachbaur D, Thurner L, Hindah H, Zeiser R, Maier C, Bethge W, Müller LP. High mortality of COVID-19 early after allogeneic stem cell transplantation – a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Transplantation and Cellular Therapy 2022. [DOI: 10.1016/j.jtct.2022.03.010] [Reference Citation Analysis]
26 Devaux CA, Melenotte C, Piercecchi-Marti MD, Delteil C, Raoult D. Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19? Front Med (Lausanne) 2021;8:663708. [PMID: 34552938 DOI: 10.3389/fmed.2021.663708] [Reference Citation Analysis]
27 Dowey R, Iqbal A, Heller SR, Sabroe I, Prince LR. A Bittersweet Response to Infection in Diabetes; Targeting Neutrophils to Modify Inflammation and Improve Host Immunity. Front Immunol 2021;12:678771. [PMID: 34149714 DOI: 10.3389/fimmu.2021.678771] [Reference Citation Analysis]
28 Al-Nesf MAY, Abdesselem HB, Bensmail I, Ibrahim S, Saeed WAH, Mohammed SSI, Razok A, Alhussain H, Aly RMA, Al Maslamani M, Ouararhni K, Khatib MY, Hssain AA, Omrani AS, Al-Kaabi S, Al Khal A, Al-Thani AA, Samsam W, Farooq A, Al-Suwaidi J, Al-Maadheed M, Al-Siddiqi HH, Butler AE, Decock JV, Mohamed-Ali V, Al-Ejeh F. Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. Nat Commun 2022;13:946. [PMID: 35177642 DOI: 10.1038/s41467-022-28639-4] [Reference Citation Analysis]
29 Boutron I, Chaimani A, Devane D, Meerpohl JJ, Rada G, Hróbjartsson A, Tovey D, Grasselli G, Ravaud P; Cochrane Emergency and Critical Care Group. Interventions for the prevention and treatment of COVID-19: a living mapping of research and living network meta-analysis. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013769] [Cited by in Crossref: 11] [Article Influence: 5.5] [Reference Citation Analysis]
30 Xu J, Xiao W, Liang X, Shi L, Zhang P, Wang Y, Wang Y, Yang H. A meta-analysis on the risk factors adjusted association between cardiovascular disease and COVID-19 severity. BMC Public Health 2021;21:1533. [PMID: 34380456 DOI: 10.1186/s12889-021-11051-w] [Reference Citation Analysis]
31 Tleyjeh IM, Kashour Z, Riaz M, Hassett L, Veiga VC, Kashour T. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update. Clin Microbiol Infect 2021;27:1076-82. [PMID: 33915284 DOI: 10.1016/j.cmi.2021.04.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Laurie K, Holcomb D, Kames J, Komar AA, DiCuccio M, Ibla JC, Kimchi-Sarfaty C. In Silico Evaluation of Cyclophilin Inhibitors as Potential Treatment for SARS-CoV-2. Open Forum Infect Dis 2021;8:ofab189. [PMID: 34109257 DOI: 10.1093/ofid/ofab189] [Reference Citation Analysis]
33 Su Z, Cheshmehzangi A, McDonnell D, Šegalo S, Ahmad J, Bennett B. Gender inequality and health disparity amid COVID-19. Nurs Outlook 2021:S0029-6554(21)00202-5. [PMID: 34774306 DOI: 10.1016/j.outlook.2021.08.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Goldman JD, Robinson PC, Uldrick TS, Ljungman P. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J Immunother Cancer 2021;9:e002630. [PMID: 34117116 DOI: 10.1136/jitc-2021-002630] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Zhang M, Bai X, Cao W, Ji J, Wang L, Yang Y, Yang H. The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence. Front Immunol 2021;12:677957. [PMID: 34335579 DOI: 10.3389/fimmu.2021.677957] [Reference Citation Analysis]
36 Zhou B, Li S, Ye J, Liu Y, Hu L, Tang Y, Wu Z, Zhang P. Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19. Int Immunopharmacol 2021;101:108254. [PMID: 34710657 DOI: 10.1016/j.intimp.2021.108254] [Reference Citation Analysis]
37 Solanich X, Padullés N, Niubó J, Videla S, Antolí A, Rocamora-Blanch G, Corbella X. Inhibition of SARS-CoV-2 replication using calcineurin inhibitors: are concentrations required clinically achievable? J Intern Med 2021;289:926-7. [PMID: 33634528 DOI: 10.1111/joim.13264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Solanich X, Antolí A, Rocamora-Blanch G, Padullés N, Fanlo-Maresma M, Iriarte A, Mitjavila F, Capdevila O, Riera-Mestre A, Bas J, Vicens-Zygmunt V, Niubó J, Calvo N, Bolivar S, Rigo-Bonnin R, Mensa-Vilaró A, Arregui L, Tebe C, Videla S, Hereu P, Corbella X. Methylprednisolone Pulses Plus Tacrolimus in Addition to Standard of Care vs. Standard of Care Alone in Patients With Severe COVID-19. A Randomized Controlled Trial. Front Med (Lausanne) 2021;8:691712. [PMID: 34195214 DOI: 10.3389/fmed.2021.691712] [Cited by in F6Publishing: 1] [Reference Citation Analysis]